KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Accumulated Depreciation & AmortizationEBIATLeasesMachine, Furnitures, Fixtures & OtherNon-Current ReceivablesOther Gross PP&E AdjustmentsProperty, Plant & Equipment (Gross)Shares Issued
Ratios

Castle Biosciences (CSTL) Accumulated Depreciation & Amortization: 2018-2025

Historic Accumulated Depreciation & Amortization for Castle Biosciences (CSTL) over the last 7 years, with Sep 2025 value amounting to $16.8 million.

  • Castle Biosciences' Accumulated Depreciation & Amortization rose 46.75% to $16.8 million in Q3 2025 from the same period last year, while for Sep 2025 it was $59.4 million, marking a year-over-year increase of 52.16%. This contributed to the annual value of $12.8 million for FY2024, which is 58.22% up from last year.
  • Castle Biosciences' Accumulated Depreciation & Amortization amounted to $16.8 million in Q3 2025, which was up 8.53% from $15.5 million recorded in Q2 2025.
  • Castle Biosciences' Accumulated Depreciation & Amortization's 5-year high stood at $16.8 million during Q3 2025, with a 5-year trough of $1.1 million in Q3 2021.
  • For the 3-year period, Castle Biosciences' Accumulated Depreciation & Amortization averaged around $10.7 million, with its median value being $10.3 million (2024).
  • Per our database at Business Quant, Castle Biosciences' Accumulated Depreciation & Amortization spiked by 815.13% in 2021 and then dropped by 5.81% in 2023.
  • Castle Biosciences' Accumulated Depreciation & Amortization (Quarterly) stood at $3.0 million in 2021, then surged by 157.99% to $7.8 million in 2022, then increased by 3.35% to $8.1 million in 2023, then skyrocketed by 58.22% to $12.8 million in 2024, then skyrocketed by 46.75% to $16.8 million in 2025.
  • Its Accumulated Depreciation & Amortization stands at $16.8 million for Q3 2025, versus $15.5 million for Q2 2025 and $14.2 million for Q1 2025.